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In recent years several re latively sensitive 
methods for determining cyclic guanosine mono-
phosphate (cGMP) content have been developed 
[1-5]. The practical limit. of detection for most of 
these assays has been found to be about 0.1 
picomoles (100 femtomolesl. Recently. a modifica-
tion of the original radioimmunoassay developed 
by Steiner et al [1 ] was reported by Cailla et al [6]. 
This method involved succinylation of cGMP sam-
ples at the 2' -0 position. Substitution of the cGMP 
in this manner yielded a binding ligand which was 
more similar in tructure to the original immuno-
gen which was used to raise anti-cGMP antibody. 
The consequence of this modification was an 
apparent increase in binding affinity to anti-cGMP 
antibody which led to a 50- to lOO-fold increase in 
sensitivity. With this assay it was reported that 
less than 1 femtomole of cGMP could be detected . 
This method was found to have one disadvantage; 
the free succinate generated by the hydrolysis of 
succinic anhydride was found to interfere with 
antibody ligand binding or compete for some of the 
sites on the antibody and therefore decreased assay 
sensitivity. Because of this . CaiJIa et al were forced 
to dilute their succinylation reaction mixture prior 
to radioimmunoassay, thus partially negating the 
increase in sensitivity achieved by the forced 
dilution factor of this method. At least part of this 
inhibition can be prevented , according to Duell: 
by inclusion in the assay of millimolar magnesium. 
It was speculated that the mechanism of this effect 
might be that the metal cation acted as a chelate 
for the excess succinate. However, under the condi-
tions of the succinylation assay, it would be 
expected that the molar concentration of free 
succinate would still be far in excess of the metal 
ion concentration used by Duell. Attempts have 
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been made to circumvent t his problem . This has 
led to t he simultaneous and independent develop-
ment of a slightly modified assay in the laborato-
ries of Goldberg [7] and Brooker [8]. 
In Goldberg's laboratory, instead of substituting 
succinate in the 2' -0 position of the cyclic nucleo-
tide, acetic anhydride is used. t.O acylate the cyclic 
nucleotide in aqueous solution. With the use 01 
acetic anhydride, little or no inhibition of binding 
has been observed and no d ilution of the acetylated 
reaction mixture is required before assay, thereby 
rendering the assay up to lOO-fold more sensit ive 
than the original assay of Steiner et al [1]. In d irect 
comparisons between the succinylation a say and 
the acety lation assay, Goldberg and co-workers 
found no significant differences in the sensitivity of 
the two assays, Jeading to the conclusion that 
sim ple subst itution at the 2' -0 position is the only 
requirement for an increased sensitivity . A wide 
variety of antibodies was not tested so that it is not 
possible to state that all antibodies will exhibit 
similar sensitivity to the 2'-0 succinylation or 
acetylation. 
During the development of the acetylation 
assay. sporadic stimulation of antigen- an tibody 
binding was observed in response to impurities in 
ti sue sam ples or in reagents used to purify tissue 
samples. This phenomenon was studied in some 
detail and a variety of pure chern icals was tested 
for their abili ty to stimulate antigen binding. I t 
was found that certain metal cations could en-
hance antibody binding by as much as 2.5-fold. 
The specific cation required varied with antibodies 
from different. sources. Of various commercial and 
noncom mercial antibodies on hand , either magne-
sium or calcium at optimal concentrations of 1 and 
10 mM, respectively. was found to elicit this effect. 
Every antibody tested wa found to be sensitive to 
a metal cation stimulation. T herefore. appropriate 
concentrations of metal cation are rou tinely in-
cluded in the acetylated radioimmunoassay. Since 
adoption of this procedure, stimulation of antigen 
bind ing by variou samples has no longer been 
observed . 
Depending upon the specificity of the antibody 
used and the type of tissue sample assayed, purifi -
cation of tissue samples before assay may be 
required . In addition, variations in the rad ioim· 
munoassay can result in a ltered cross- reactivit ies 
For exam ple, with one cGMP antibody it has been 
found that cross-reactivity with cyclic adenosint' 
monophosphate (cAMP) was 1:300 at pH 6.2 befor, 
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acetylation or succinylation, 1: 100 at pH 6.2 after 
acetylation, and 1: 15 at pH 4.75 afte r acety lat ion 
under the cond itions described by Harper and 
Brooker [8). It was found t hat in many situations 
enough cAMP cross-reacted in the cG MP assay to 
essentially nega te the validity of cGMP measure-
ments. Therefore, the importance of carrying out 
cross-reactivity studies on both commercial and 
noncommercial antibodies before and after substi-
tution of t he cyclic nucleotide in question is 
emphasized. Both Parker' and Voorhees' have 
reported t hat it is not possible to correlate an-
tibody titer with antibody specificity . In other 
words. a high-titer antibody for one cyclic nucleo-
tide doe not necessari ly imply high specificity. 
Likewise, a low-titer antibody may well have 
superior specificity properties, but this is not a 
general rule and each case must be carefully 
examined . 
In the procedure described by Har per and 
Brooker 18) it was claimed t hat no ti sue purifica-
tion was required fo r t he assay of cGMP using the 
acetylation method. According to Duel\" it is not 
possi ble, using the succinylation assay, to assay 
epidermal cyclic nucleotide levels withou t purifi -
cation, and considerable interference in the assay 
was observed without purifIcation. Of se\'eral anti-
bodies tested in Goldberg's laboratory none ..... as 
found suitable for assay ing unpurified cGMP 
samples. In their experience the only situat ion 
Lhat mi~ht not requi re prior purification would be 
one in which a la rge dilution of the sample was 
possible before assaying cGMP. With respect to 
the use of the acelylated or succinylated radio-
immunoassay for cAMP. prior purifica t ion of sam-
ples may not be required. Because the level of 
cAMP in tissues exceeds cG MP by 10- to lOO-fold. 
the additional margin of safety by dilution of 
samples may be enough to lower the concentra-
tions of nonspecific su bstances, such as other 
5' -adenine nucleotides. enough so as to avoid 
nonspecific d isplacement of labeled antigen from 
the a ntibody. In Parker's laboratory. cAMP am-
pies are not purified before assay. * 
A new problem has developed with the advent of 
such extremely sensitive cyclic nucleotide assays. 
T he ability of cyclic nucleotide phosphodiesterase 
to completely destroy assayable material has gen-
erally been used as the criterion for ult.imate 
specifici ty of a given assay. In our experience 
com merc ia l preparations of beef heart phosphodi-
esterase are not capable of complet.ely hydrolyzing 
the ext remely low concentrations of cGMP and 
cAMP detectable with t he new assay procedures 
after 3-hr incubations. Therefore. it is quite easy to 
conclude that the assay is not specific because of 
readable blank material in the assay that is not 
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hydrolyzed by phosphodiesterase. However, with 
t he use of serial dilution of samples and parallel 
line analysis, it can be easily verified whether or 
not there is any nonspecific assayable mater ial in a 
given sample. E ven after partial purifica tion [9] of 
cAMP and cGMP, some tissues exhibited non-
specific cross-react ing material. It is necessary, 
therefore , to exmine this problem with each new 
experimental system. 
Of t he various radiotracer assays for guanylate 
cyclase and phosphodiesterase which have been 
developed, tbose developed by H ardm an and co-
workers [9,10J and described by Garbers' have 
proved to be reliable and accurate. Alternately. 
the acetvlated radioimmunoassay has been used 
to meas;re guanylate cyclase in G'oldberg's labora-
tory. With an appropriate antibody. no prior sepa-
ration of cG MP from the GTP substrate is 
required . It is necessary, however, to test the 
various reaction components in the guanylate 
cyclase assay for interference in the cG MP radio-
immunoassay. 
In conclusion, t he assay method of choice for 
determining intracellular - cGMP content would 
appear to be the newly developed substitution 
radioimmunoassays . The acetylation assay, as de-
veloped by Goldberg et al (7 ) and Harper and 
Brooker (8) is superior to t he succinylation assay, 
in t hat (1 ) it is possible to achieve the full increase 
in sensitivity capable of the method. and (2) it is 
methodologically less cumbersome to u e. In gen-
eral. prior purification of cG MP samples before 
a sa .... is still requ ired until proven otherwise. even 
with these new assays. Such rigid purification may 
not be necessary for the assay of cAMP. 
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